NASDAQ$NKTX
Nkarta Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Nkarta reported financial results for the third quarter ended September 30, 2022.
Nkarta reported a net loss of $28.3 million for the third quarter of 2022. As of September 30, 2022, Nkarta had cash, cash equivalents, restricted cash, and short-term investments of $395.1 million.
- NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022
- NKX019 Phase 1 clinical trial recently opened dose expansion cohorts
- Next NKX019 clinical update is expected by year-end 2022
- Next NKX101 clinical update is expected in first half of 2023
Headline financials
Revenue & EPS history
Nkarta · Revenue · Quarterly
$0
Forward guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
+0.9%
Avg return
Earnings day
-2.2%
Avg return
5 days after
-0.9%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+16.2%
Q4 2021
Best reaction
-30.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.9% | -14.8% | — | |
| Q1 2026 | +3.5% | -16.1% | -13.2% | |
| Q3 2025 | +3.1% | -4.6% | -4.6% | |
| Q2 2025 | +12.8% | +19.9% | +0.5% | |
| Q1 2025 | +1.2% | -0.6% | -4.6% | |
| Q4 2024 | +3.2% | -15.4% | +13.3% | |
| Q3 2024 | -4.8% | -9.0% | -23.0% | |
| Q2 2024 | +1.2% | +0.0% | +10.3% | |
| Q1 2024 | -2.3% | +2.3% | +3.1% | |
| Q4 2023 | -30.3% | -22.8% | -43.0% | |
| Q3 2023 | -5.6% | +7.0% | +27.0% | |
| Q2 2023 | -0.5% | -1.0% | -20.5% | |
| Q1 2023 | -4.1% | -4.1% | -0.9% | |
| Q4 2022 | +1.3% | -7.1% | +19.3% | |
| Q3 2022 | -8.4% | -2.1% | -35.5% | |
| Q2 2022 | +8.8% | +11.1% | -8.5% | |
| Q1 2022 | +12.8% | +11.1% | +6.9% | |
| Q4 2021 | +16.2% | +6.2% | -15.2% | |
| Q3 2021 | +7.7% | +7.2% | -15.0% | |
| Q2 2021 | -1.9% | -5.0% | -29.0% | |
| Q4 2020 | +0.0% | -14.4% | -30.3% | |
| Q3 2020 | +2.9% | +14.5% | +122.0% | |
| Q2 2020 | -7.0% | -12.0% | +21.1% | |
| Q1 2021 | +11.3% | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro